Key facts
- iFAST’s last known valuation is $16.4M.
- It has raised $8.9M; the latest was Seed Round ($6.5M) in Nov 2024.
- Notable investors include Future Planet Capital, UK Innovation & Science Seed Fund, Conduit Connect, Incate, KCP Nominees — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for iFAST
- ·The full record, as it builds
Funding rounds
No funding rounds for iFAST are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iFAST
Operator of a medical research company intended to reduce the threat of antimicrobial resistance. The company facilitates antimicrobial susceptibility test systems to avoid the growth of bacteria in the sample and determines the optimum antibiotic for clinicians to prescribe, enabling researchers to improve the outcomes.
- Sector
- Healthcare
- HQ
- Whiteley, United Kingdom
- Founded
- 2022
- Employees
- 22
- Website
- ifastdiagnostics.com/
- Ownership
- Privately Held (backing)
iFAST doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iFAST shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iFAST in its N-PORT filings yet. We sweep new filings monthly.